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policies for device utilization and future development however, it is impera- 
tive to describe the charsctedstice of these patients. To this end, we studied 
the age at initial implant for 35,533 patients who underwent ICD surgery in the 
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Result: During this time period, mean age at initial ICD implant increased 
from 60.0 yrs to 63.4 yrs. Regression analysis howed an average increase 
in age at implant of 140 days/yr (p -~ 0.001). Although the overall mean age 
for females was lower than for males (60 ± 12.6 yrs vs. 62.5 ± 10.6 yrs, p 
< 0.001), there was no difference in the average increase in age for each 
year of observation. The proportion of pts of Medicare-eligible age (>_ 65 yr) 
increased from 39% in 1986 to 53% in 1994 (p < 0.001). The US population 
>_. 65 yrs old, increased from 12.1% to 12.8% over the same time period. 
Conclusions: I) Future public policy decisions regarding Medicare funding 
of devices and other invastigationat medical procedures must consider the 
Increasing age of recipients of that technology. 2) Specifically for ICD, our 
find;ngs uggest hat by the year 2000, two-thirds of all patients receiving an 
ICD will be of Medicare age. 
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~High  Rate Silent Cerebral Infarction Annual Event of 
in Patients With Nonvalvular Atrial Fibrillation 
Yukihiro Koretsune, Masatsugu Hod, Takenobu Kamada, The First 
Department of Medicine, Osaka, Japan; Osaka University School of 
Medicine, Osaka, Japan; COOPAT (Cooperative Osaka Platelet 
Antiaggregation Trial) STUDY GROUP, Osaka, Japan 
Nonvalvular atrial fibrillation (NVAF) increases the risk of stroke almost six 
fold, however, the incidence of silent cerebral infarction (SCI) is unclear. 
To study the annual event rate of SCI in patients with NVAF, 100 patients 
(68 male, 32 female; 59 continuous, 41 paroxysmal; age, 62.0 :E 1.0, mean 
± SEE) without history of cerebrovascular ccident underwent clinical eval- 
uation, ECG, 2D and M mode Echo/Dopptsr-cardiogrsphy. Brain magnetic 
resonance imagings (MRI, T1- and T2-weighted, and Proton images) were 
determined twice with 12 months interval. None of these patients had re- 
ceived anticoagulant or antiplatelet therapy. Percent fractional shortening of 
left vemricular wall was ,98 ± 5.5%. SCI were detected in 84% of patients (age 
50': 70','°, 60': 95%, 70': 100%) in the initial MRI. There was no significant 
difference in the prevalence of SCI between paroxysmal nd continuous At. 
The average number of infarcted foci was 31.1 ± 5.5 (range: 0 to 193) per 
patient. Dudng a follow-up of 12 months, the rate of SCI was 25% per year. 
Locations of new infarcted foct were in the white-matter (12°/,,), the deep 
white-matter (60%), basal ganglion (28%), thalamus (4"/0) and brain stem 
(12°/o). 
Thus, we conclude that the annual event rate of SCI is quite common in 
patients with NVAF. 
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~ Lipoprotein(a) as a Determinant of CHD in Younger 
Women 
Kdstina Odh-Gom~r, Murray A. Mittleman, Kadn Schenck-Gustafsson, 
tars Ryd(~n. Karolincka Institute, Stockholm, Sweden; Karolinska Hospital, 
Stockholm, Sweden; Institute for Prevention of Cardiovascular Disease, 
Boston, MA; Deaconess Hospital, Boston, MA 
Lp(a) appears to be a dsk factor for CHD in men. However the role of 
Lp(a) In women is less clear. We examined the ability of Lp(a) to predict 
DHD in a popolation-besed case-control study of women aged 65 or under, 
living in the greater Stockholm area. Cases were all patients hospitalized 
for an acute CHD event between Feb. 1991 and Feb. 1994. Controls were 
randomly selected from the city census and were matched to cases by age 
end catchment area. Lp(a) was measured using an immunoturbidomatric 
method (Incstar) calibrated to the Northwest Lipid Research Laboratories 
(CV < 9%), 
Of the 292 consecutive cases, 109 (37%) were hospitalized for an acute 
MI and 182 (63%0) for angina pectoris. The mean age in both groups was 56 
± 7 years. 74 patients (25%,) and 84 controls (29%) were prsmenopausal. 
The distflbutions of Lp(a) were highly skewed in both cases and controls 
with a r'lnge from 0.1 to 114 mg/dl. Age-adjusted odds ratios for CHD in the 
highest versus the lowest quartile of Lp(a) was 2,1 (95% CI 1.1,3.4). Adjusting 
for age, smoking, education, body mass index, systolic blood pressure, total 
cholesterol, triglyceddes, and HDL, the odds ratio was 2.6 (95% CI 1.5, 4.4), 
The odds ratios were similar when cempedng MI and angina patients with 
their respective controls. The odds ratios were 4.3 (95% Cl 1.2, 15.1), and 
2.3 (95% 1,2, 4,2) in pre and postmenopausal women respectively. 
These results uggest hat Lp(a) is a determinant of CHD in both pre and 
postmenopaucal women. 
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Hospital, Boston,/VIA; Harvard Medical School, Boston, MA 
Background: Evidence suggests that lipid-lowering medications decrease 
mortality in patients (pts) with coronary artery disease (CAD) and hypedipi- 
demia; it has been suggested that LDL be the target of therapy with the 
goal < 100 mg/dL. The purpose of this study was to estimate how frequently 
pts with CAD and hypedipidemia are prescdbed lipid-lowering medications 
and achieve target LDL in clinical practice. Methods: We prospectively iden- 
tified pts with known CAD electively admitted to the intermediate cardiac 
care service at an urban, university affiliated hospital. All pts were cared for 
by a cardiologist. Fasting lipid profiles were tested on admission. Results: 
Fifty-two pts were studied (mean age(sd) 61(15)yr; 77% male; 96% admitted 
for angiography and/or revascutsrization; 71% hypertensive; 27°/, diabetic). 
Eighty-one percent had LDL > 100 mg/dL, of whom 31% were on lipid- 
iowedng agents. In contrast, 100%o with hypertension (p < 0.0001) and 92=/0 
of diabetics (p < 0.0001) received medical therapy for those dsk factors, and 
98'/= were on aspidn (p = 0.0001). Of all pts on lipid-lowedng agents, only 
38% had achieved target LDL _< 100 rag/alL. HMG-CoA reductase tnhibitors 
were more commonly prescribed (25%) than all other lipid agents combined. 
Of all pts, only 6% were at target LDL _< 100 mg/dL with dietary therapy alone. 
Conclusion: We conclude that 1) The majority of pts eligible for lipid-lowering 
agents do not receive it; 2) For pts who receive therapy, the suggested target 
LDL is often not attained; 3) Hypertension and diabetes are treated much 
more frequently than hyperlipidemla. 
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The National Cholesterol Education Program: ATP II (NCEP) has established 
new aggressive goals for lipid treatment in patients with coronary artery 
disease (CAD), which reduces recurrent CAD events in clinical trials. It 
is unknown how often these goals are actually achieved in the pdmary 
care setting, or whether these guidelines have influenced treatment. We 
studied 1,934 veterans with known CAD having lipid testing between 1991- 
93 and followed for 22.3 ± 10.2 (mean ± so) months, 1 year after release of 
NCEP:ATP II guidelines. Dyslipldemla (LDL > 130, TG > 200, or HDL < 35) 
was initially present in 1580 patients (82%). Mean LDL was 144 ± 48, total 
cholasteml 216 ± 46, and HDL 40 :E 16 mg/dL In 61% LDL was • 130, the 
previous NCEP target. At followup 34% of patients failed to meet he revised 
NCEP target (LDL < 100) and 59% had an LDL > 130. Mean followup lipids 
were unchanged from initial values. A mean of 4.5 -t- 3.7 lipid profiles were 
drawn per patient. Lipid-lowedng drugs were used in 32%0, but these patients 
did not reach LDL goal any more often than those not on drugs, Reasons for 
not achieving a LDL < 100 were failure to use lipid drugs (37%), inadequate 
dose and/or bose-limiting side effects when drugs were used (24%), and 
failure to retest lipide (2L~o). 
Needy all in this high dsk population have dyslipidernia requldng Interven- 
tion by NCEP cdteda; few reach target LDL levels, and lipid treatment did not 
improve after 2 year followup, Substantial cost and effort are expended in 
testing and attempting to treat dyslipidemic CAD patients in the primary care 
setting, but fail to achieve optimum lipid lowering. More effective treatment 
strategies must be implemented before the benefits of lipid Iowedng can be 
achieved outside of clinical trials. 
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~91"~ Acute Contrast Nephropsthy After Coronary 
Intervention: Incidence, Risk Factors, and 
Relationship to Mortality 
Peter A. McCullough, Robert Wolyn, Leslie L. Rocher, Robert N. Levin, 
William W. O'Neill. William Beaumont Hospital, Royal Oak, Michigan 
Previous studies of contrast naphropathy have identified reduced baseline 
renal function, diabetes, congestive heart failure, and contrast volume as 
risk factors for renal failure post-artedography. The reported incidences of a 
rise In serum creatinine and renal failure requiring dialysis vary widely. The 
relationships between these events and mortality am not well understood. 
This retrospective cohort study of 1828 patients included all interventional 
